Browse > Article
http://dx.doi.org/10.15324/kjcls.2022.54.2.133

Trends of Antifungal Agent Susceptibility of Candida Strains Isolated from Blood Cultures in 2009~2018  

Hwang, Yu-Yean (Department of Laboratory Medicine, Samsung Medical Center)
Kang, On-Kyun (Department of Laboratory Medicine, Samsung Medical Center)
Park, Chang-Eun (Department of Biomedical Laboratory Science, Molecular Diagnostics Research Institute, Namseoul University)
Lee, Moo-Sik (Department of Health Sciences, The Graduate School of Konyang University)
Kim, Young-Kwon (Department of Health Sciences, The Graduate School of Konyang University)
Huh, Hee-Jae (Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Nam-Yong (Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Korean Journal of Clinical Laboratory Science / v.54, no.2, 2022 , pp. 133-141 More about this Journal
Abstract
Candida is one of the most common causes of bloodstream infections and a leading cause of morbidity and mortality among hospitalized patients. The purpose of this study was to provide important information for formulating empirical treatment plans for candidemia by investigating the antifungal resistance rate of Candida. Among the Candida strains (973 cases) isolated from blood culture tests at the S hospital in 2009~2018, 4.7% (N=44) comprising the Candida spp. (932 strains) showed resistance to fluconazole. The resistant strains included C. albicans, C. parapsilosis, C. tropicalis, and C. glabrata. In addition Candida spp. (947 strains) showed resistance to amphotericin B (N=6, 0.6%), flucytosine (N=23, 2.4%) and voriconazole (N=24, 3.1%). C. albicans was resistant to fluconazole (N=23, 6.9%) and voriconazole (N=21, 6.0%), The statistical analysis showed that C. albicans and non-albicans Candida species were resistant to fluconazole (P=0.039) and voriconazole (P<0.001). A monitoring system to understand the rate of candidiasis infections in a hospital setting is required. It is also important to make the right choice of the antifungal agent based on drug susceptibility patterns. Therefore, an infection surveillance policy that tracks Candida resistance through regular antifungal susceptibility tests is necessary.
Keywords
Antifungal agent susceptibility; Blood culture; Candidemia; Candida bloodstream infections; Candida species;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect. 2015;21:337-343. https://doi.org/10.1016/j.cmi.2014.11.022   DOI
2 Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317. https://doi.org/10.1086/421946   DOI
3 Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:662-678. https://doi.org/10.1086/313749   DOI
4 St-Germain G, Laverdiere M, Pelletier R, Bourgault AM, Libman M, Lemieux C, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol. 2001;39:949-953. https://doi.org/10.1128/JCM.39.3.949-953.2001   DOI
5 Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015;41:285-295. https://doi.org/10.1007/s00134-014-3603-2   DOI
6 Chae MJ, Shin JH, Cho D, Kee SJ, Kim SH, Shin MG, et al. Antifungal susceptibilities and distribution of Candida species recovered from blood cultures over an 8-year period. Korean J Lab Med. 2003;23:329-335.
7 Hesstvedt L, Gaustad P, Andersen CT, Haarr E, Hannula R, Haukland HH, et al. Twenty-two years of candidaemia surveillance: results from a Norwegian national study. Clin Microbiol Infect. 2015;21:938-945. https://doi.org/10.1016/j.cmi.2015.06.008   DOI
8 Vallabhaneni S, Mody RK, Walker T, Chiller T. The global burden of fungal diseases. Infect Dis Clin North Am. 2016;30:1-11. https://doi.org/10.1016/j.idc.2015.10.004   DOI
9 Lackner M, de Hoog GS, Verweij PE, Najafzadeh MJ, Curfs-Breuker I, Klaassen CH, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother. 2012;56:2635-2642. https://doi.org/10.1128/AAC.05910-11   DOI
10 World Health Organization. Antimicrobial resistance global report on surveillance 2014 [Internet]. [cited 2022 January 14]. Available from: https://apps.who.int/iris/bitstream/handle/10665/112647/WHO_HSE_PED_AIP_2014.2_eng.pdf
11 Cho EJ, Shin JH, Kim SH, Kim HK, Park JS, Sung H, et al. Emergence of multiple resistance profiles involving azoles, echinocandins and Amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia. J Antimicrob Chemother. 2015;70:1268-1270. https://doi.org/10.1093/jac/dku518   DOI
12 Healey KR, Zhao Y, Perez WB, Lockhart SR, Sobel JD, Farmakiotis D, et al. Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat Commun. 2016;7:11128. https://doi.org/10.1038/ncomms11128   DOI
13 Horn DL, Fishman JA, Steinbach WJ, Anaissie EJ, Marr KA, Olyaei AJ, et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis. 2007;59:407-414. https://doi.org/10.1016/j.diagmicrobio.2007.06.008   DOI
14 Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B, Chiller TM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One. 2015;10:e0120452. https://doi.org/10.1371/journal.pone.0120452   DOI
15 WHO. Antimicrobial Resistance: Global Report on Surveillance [Internet]. 2014. [cited 2022 January 22]. Available from: https://apps.who.int/iris/handle/10665/112642
16 Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and Voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001;39:3254-3259. https://doi.org/10.1128/JCM.39.9.3254-3259.2001   DOI
17 Khan Z, Ahmad S, Al-Sweih N, Mokaddas E, Al-Banwan K, Alfouzan W, et al. Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a12-year period in Kuwait Ziauddin Khan. PLOS one. 2019;14:e0216250. https://doi.org/10.1371/journal.pone.0216250   DOI
18 Rodriguez L, Bustamante B, Huaroto L, Agurto C, Illescas R, RamirezR, et al. A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes. PLoS One. 2017;12:e0175172. https://doi.org/10.1371/journal.pone.0175172   DOI
19 Vallabhaneni S, Cleveland AA, Farley MM, Harrison LH, Schaffner W, Beldavs ZG, et al. Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008-2014. Open Forum Infect Dis. 2015;2:ofv163. https://doi.org/10.1093/ofid/ofv163   DOI
20 Lopez Dupla M, Martinez JA, Vidal F, Almela M, Lopez J, Marco F, et al. Clinical characterization of breakthrough bacteraemia: a survey of 392 episodes. J Intern Med. 2005;258:172-180. https://doi.org/10.1111/j.1365-2796.2005.01513.x   DOI
21 Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect. 2013;19:501-509. https://doi.org/10.1111/1469-0691.12195   DOI
22 Antinori S, Milazzo L, Sollima S, Galli M, Corbellino M. Candidemia and invasive candidiasis in adults: A narrative review. Eur J Intern Med. 2016;34:21-28. https://doi.org/10.1016/j.ejim.2016.06.029   DOI
23 Kett DH, Azoulay E, Echeverria PM, Vincent JL; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39:665-670. https://doi.org/10.1097/CCM.0b013e318206c1ca   DOI
24 Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, De Pascale G, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med. 2014;40:839-845. https://doi.org/10.1007/s00134-014-3310-z   DOI
25 Kim JS, Gong SY, Kim JW, Rheem I, Kim GY. Antimicrobial susceptibility patterns of microorganisms isolated from blood culture during the last 8 years: 2010-2017. Korean J Clin Lab Sci. 2019;51:155-163. https://doi.org/10.15324/kjcls.2019.51.2.155   DOI
26 Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-e50. https://doi.org/10.1093/cid/civ933   DOI
27 Colombo AL, Guimaraes T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med. 2014;40:1489-1498. https://doi.org/10.1007/s00134-014-3400-y   DOI
28 Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36:1221-1228. https://doi.org/10.1086/374850   DOI